Pub Date : 2024-05-01Epub Date: 2024-03-20DOI: 10.12788/fp.0462
Jake A Cresta, Michael A Pavio, Jamie L Lombardo, John G McCarthy, Allison M Bush
Background: Characterizing multiple hepatic lesions on cross-sectional imaging, particularly differentiating abscesses from metastatic lesions, can be challenging.
Case presentation: A male aged 53 years with a history of chromophobe renal cell carcinoma presented with fevers and abdominal pain and was found to have multiple hepatic lesions concerning for hepatic abscesses. The lesions initially evaded diagnosis on imaging, laboratory tests, and biopsy, but ultimately were determined to be a rare case of metastatic chromophobe renal cell carcinoma of the liver.
Conclusions: The finding of multiple new liver lesions on imaging during a febrile illness is concerning for hepatic abscess or malignancy, which can be difficult to diagnose with imaging alone. Differentiation between infectious and neoplastic etiologies may require additional imaging and/or tissue sampling.
{"title":"A Case of Metastatic Chromophobe Renal Cell Carcinoma Masked as Suspected Hepatic Abscesses.","authors":"Jake A Cresta, Michael A Pavio, Jamie L Lombardo, John G McCarthy, Allison M Bush","doi":"10.12788/fp.0462","DOIUrl":"10.12788/fp.0462","url":null,"abstract":"<p><strong>Background: </strong>Characterizing multiple hepatic lesions on cross-sectional imaging, particularly differentiating abscesses from metastatic lesions, can be challenging.</p><p><strong>Case presentation: </strong>A male aged 53 years with a history of chromophobe renal cell carcinoma presented with fevers and abdominal pain and was found to have multiple hepatic lesions concerning for hepatic abscesses. The lesions initially evaded diagnosis on imaging, laboratory tests, and biopsy, but ultimately were determined to be a rare case of metastatic chromophobe renal cell carcinoma of the liver.</p><p><strong>Conclusions: </strong>The finding of multiple new liver lesions on imaging during a febrile illness is concerning for hepatic abscess or malignancy, which can be difficult to diagnose with imaging alone. Differentiation between infectious and neoplastic etiologies may require additional imaging and/or tissue sampling.</p>","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":"41 Suppl 2","pages":"S34-S37"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11132106/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141177070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-01Epub Date: 2024-05-15DOI: 10.12788/fp.0455
Shruthi Narasimha, Sukhjinder Chauhan, Roger Nehaul, Jeffrey Cummings, Susan Wright, Alexis Patterson, Raymond Mullins, William Messina, Brian Zilka, Ana Kraus
Background: Colonoscopy is a first-line method for colorectal cancer (CRC) screening. However, cost-effective noninvasive tests, such as high-sensitivity guaiac-based fecal occult blood test (gFOBT) and fecal immunochemical test (FIT), are also used. The COVID-19 pandemic had a substantial negative impact on CRC screening rates. The James A. Haley Veterans Affairs Hospital (JAHVAH) continued socially distant CRC screening using FITs, but encountered inefficiencies due to high rates of incorrectly collected FIT samples. A quality improvement (QI) project was conducted to increase correctly collected and testable FIT kits upon initial laboratory submission.
Observations: The ambulatory QI project sought out root causes for incorrectly returned FITs and proposed Plan-Do-Study-Act (PDSA) cycles based on a series of approved action plans. A multidisciplinary team of laboratory, nursing, administrative, and primary care staff worked together to discover 6 major root causes. Our multipronged PDSA cycle attempted to set up redundant patient reminders, centralize the FIT dispersal process, and make the patient-FIT interface more user-friendly. All PDSA solutions were implemented over 4 months. Lack of collection date was the most common reason for incorrectly returned FIT kits and the focus of PDSA improvements. The rate of FITs with missing collection dates dropped from 24% prior to PDSA to 14% in April 2021. The rate of correctly returned FIT kits rose from 38% before the project to 72% afterwards, surpassing the 20% improvement goal.
Conclusions: FIT is a useful method for CRC screening that can be particularly helpful when in-person visits are limited, as seen during the COVID-19 pandemic. The increase in demand for FITs during the pandemic revealed process deficiencies and gave JAHVAH an opportunity to improve workflow.
背景:结肠镜检查是结直肠癌(CRC)筛查的一线方法。然而,高灵敏度愈创木酚粪便潜血试验(gFOBT)和粪便免疫化学试验(FIT)等经济有效的非侵入性检查也在使用。COVID-19 大流行对 CRC 筛查率产生了很大的负面影响。James A. Haley 退伍军人事务医院 (James A. Haley Veterans Affairs Hospital,JAHVAH) 继续在社会上使用 FIT 进行远距离 CRC 筛查,但由于 FIT 样本采集错误率较高,导致筛查效率低下。该医院开展了一项质量改进(QI)项目,以提高实验室初次提交的 FIT 套件的正确采集率和可检测率:门诊质量改进项目找出了错误退回 FIT 的根本原因,并根据一系列已获批准的行动计划提出了 "计划-实施-研究-行动"(PDSA)循环。由实验室、护理、行政和基础护理人员组成的多学科团队共同努力,发现了 6 个主要的根本原因。我们多管齐下的 PDSA 循环尝试设置多余的患者提醒、集中 FIT 分散流程,并使患者-FIT 界面更加友好。所有 PDSA 解决方案均在 4 个月内实施完毕。缺少采集日期是错误退回 FIT 套件的最常见原因,也是 PDSA 改进的重点。缺少采集日期的 FIT 比例从实施 PDSA 之前的 24% 降至 2021 年 4 月的 14%。正确退回 FIT 工具包的比率从项目实施前的 38% 上升到项目实施后的 72%,超过了 20% 的改进目标:结论:FIT 是一种有效的 CRC 筛查方法,尤其是在 COVID-19 大流行期间,当上门服务受到限制时,这种方法尤其有用。大流行期间对 FIT 需求的增加暴露了流程的不足,为 JAHVAH 提供了改进工作流程的机会。
{"title":"Improving Fecal Immunochemical Test Collection for Colorectal Cancer Screening During the COVID-19 Pandemic.","authors":"Shruthi Narasimha, Sukhjinder Chauhan, Roger Nehaul, Jeffrey Cummings, Susan Wright, Alexis Patterson, Raymond Mullins, William Messina, Brian Zilka, Ana Kraus","doi":"10.12788/fp.0455","DOIUrl":"10.12788/fp.0455","url":null,"abstract":"<p><strong>Background: </strong>Colonoscopy is a first-line method for colorectal cancer (CRC) screening. However, cost-effective noninvasive tests, such as high-sensitivity guaiac-based fecal occult blood test (gFOBT) and fecal immunochemical test (FIT), are also used. The COVID-19 pandemic had a substantial negative impact on CRC screening rates. The James A. Haley Veterans Affairs Hospital (JAHVAH) continued socially distant CRC screening using FITs, but encountered inefficiencies due to high rates of incorrectly collected FIT samples. A quality improvement (QI) project was conducted to increase correctly collected and testable FIT kits upon initial laboratory submission.</p><p><strong>Observations: </strong>The ambulatory QI project sought out root causes for incorrectly returned FITs and proposed Plan-Do-Study-Act (PDSA) cycles based on a series of approved action plans. A multidisciplinary team of laboratory, nursing, administrative, and primary care staff worked together to discover 6 major root causes. Our multipronged PDSA cycle attempted to set up redundant patient reminders, centralize the FIT dispersal process, and make the patient-FIT interface more user-friendly. All PDSA solutions were implemented over 4 months. Lack of collection date was the most common reason for incorrectly returned FIT kits and the focus of PDSA improvements. The rate of FITs with missing collection dates dropped from 24% prior to PDSA to 14% in April 2021. The rate of correctly returned FIT kits rose from 38% before the project to 72% afterwards, surpassing the 20% improvement goal.</p><p><strong>Conclusions: </strong>FIT is a useful method for CRC screening that can be particularly helpful when in-person visits are limited, as seen during the COVID-19 pandemic. The increase in demand for FITs during the pandemic revealed process deficiencies and gave JAHVAH an opportunity to improve workflow.</p>","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":"41 Suppl 2","pages":"S29-S37"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11132107/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141177133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-01Epub Date: 2024-05-11DOI: 10.12788/fp.0464
Christian Calderon, Autreen Golzar, Stephen Marcott, Kyle Gifford, Sandy Napel, Dominik Fleischmann, Fred M Baik, Thomas F Osborne, Andrey Finegersh, Davud Sirjani
Background: Three-dimensional (3D) printing has emerged as a promising new technology for the development of surgical prosthetics. Research in orthopedic surgery has demonstrated that using 3D printed customized prosthetics results in more precise implant placements and better patient outcomes. However, there has been little research on implementing customized 3D printed prosthetics in otolaryngology. The program sought to determine whether computed tomography (CT) serves as feasible templates to construct 3D printed palatal obturator prosthetics for defects in patients who have been treated for head and neck cancers.
Observations: A retrospective review of patients with palatal defects was conducted and identified 1 patient with high quality CTs compatible with 3D modeling. CTs of the patient's craniofacial anatomy were used to develop a 3D model and a Formlabs 3B+ printer printed the palatal prosthetic. We successfully developed and produced an individualized prosthetic using CTs from a veteran with head and neck deformities caused by cancer treatment who was previously treated at the Veterans Affairs Palo Alto Health Care System. This project was successful in printing patient-specific implants using CT reproductions of the patient's craniofacial anatomy, particularly of the palate. The program was a proof of concept and the implant we created was not used on the patient.
Conclusions: Customized 3D printed implants may allow otolaryngologists to enhance the performance and efficiency of surgeries and better rehabilitate and reconstruct craniofacial deformities to restore appearance and function to patients. Additional research will strive to enhance the therapeutic potential of these prosthetics to serve as low-cost, patient-specific implants.
背景:三维(3D)打印技术已成为开发外科假体的一项前景广阔的新技术。骨科手术方面的研究表明,使用三维打印定制假体可以使植入物的位置更精确,患者的治疗效果更好。然而,在耳鼻喉科中使用定制 3D 打印假体的研究却很少。该计划旨在确定计算机断层扫描(CT)是否可作为可行的模板,为接受过头颈部癌症治疗的患者构建3D打印腭钝器假体:我们对患有腭部缺损的患者进行了回顾性检查,发现 1 名患者的高质量 CT 与 3D 建模相匹配。患者颅面部解剖结构的 CT 图像被用于开发三维模型,Formlabs 3B+ 打印机打印出了腭假体。我们利用一名曾在退伍军人事务帕洛阿尔托医疗保健系统接受治疗的因癌症治疗导致头颈部畸形的退伍军人的 CT 图像,成功开发并制作了个性化假体。该项目成功地利用患者颅面部解剖结构(尤其是腭部)的 CT 复制品打印出了患者专用的假体。该项目只是概念验证,我们制作的植入体并未用于患者:定制的三维打印植入物可以让耳鼻喉科医生提高手术的效果和效率,更好地康复和重建颅面畸形,恢复患者的外观和功能。其他研究将努力提高这些假体的治疗潜力,使其成为低成本、针对特定患者的植入体。
{"title":"3D Printing for the Development of Palatal Defect Prosthetics.","authors":"Christian Calderon, Autreen Golzar, Stephen Marcott, Kyle Gifford, Sandy Napel, Dominik Fleischmann, Fred M Baik, Thomas F Osborne, Andrey Finegersh, Davud Sirjani","doi":"10.12788/fp.0464","DOIUrl":"10.12788/fp.0464","url":null,"abstract":"<p><strong>Background: </strong>Three-dimensional (3D) printing has emerged as a promising new technology for the development of surgical prosthetics. Research in orthopedic surgery has demonstrated that using 3D printed customized prosthetics results in more precise implant placements and better patient outcomes. However, there has been little research on implementing customized 3D printed prosthetics in otolaryngology. The program sought to determine whether computed tomography (CT) serves as feasible templates to construct 3D printed palatal obturator prosthetics for defects in patients who have been treated for head and neck cancers.</p><p><strong>Observations: </strong>A retrospective review of patients with palatal defects was conducted and identified 1 patient with high quality CTs compatible with 3D modeling. CTs of the patient's craniofacial anatomy were used to develop a 3D model and a Formlabs 3B+ printer printed the palatal prosthetic. We successfully developed and produced an individualized prosthetic using CTs from a veteran with head and neck deformities caused by cancer treatment who was previously treated at the Veterans Affairs Palo Alto Health Care System. This project was successful in printing patient-specific implants using CT reproductions of the patient's craniofacial anatomy, particularly of the palate. The program was a proof of concept and the implant we created was not used on the patient.</p><p><strong>Conclusions: </strong>Customized 3D printed implants may allow otolaryngologists to enhance the performance and efficiency of surgeries and better rehabilitate and reconstruct craniofacial deformities to restore appearance and function to patients. Additional research will strive to enhance the therapeutic potential of these prosthetics to serve as low-cost, patient-specific implants.</p>","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":"41 Suppl 2","pages":"S3-S7"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11132111/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141177119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01Epub Date: 2024-02-21DOI: 10.12788/fp.0456
Lisa Hsi, Shannon Ruiz
Background: Acute agitation frequently occurs in the emergency department. Appropriate management is critical for the safety of all parties involved. Benzodiazepines and antipsychotics are commonly used for agitation, but safety concerns exist with these medications in older adults, even with acute use. The purpose of this study was to compare prescribing practices of anti-agitation medications between adults aged 18 to 64 years and those aged ≥ 65 years.
Methods: This study was a retrospective chart review of patients who presented to the Veteran Affairs Southern Nevada Healthcare System emergency department and received haloperidol, droperidol, lorazepam, olanzapine, or ziprasidone from August 1, 2019, to July 31, 2022. Veterans were excluded if they had alcohol intoxication, alcohol withdrawal, benzodiazepine withdrawal, or medication administration unrelated to agitation. Safety outcomes included oxygen saturation < 95%, supplemental oxygen use, intubation, QTc prolongation, and new hypotension within 1 hour of medication administration.
Results: For the 232 patients who met inclusion criteria, baseline characteristics differed significantly. When comparing patients aged 18 to 64 years and those aged ≥ 65 years, the younger cohort had higher rates of substance use disorder diagnosis (55.3% vs 27.5%, P < .001), positive urine drug screen (69.7% vs 22.5%, P < .001), and 72-hour legal hold (59.9% vs 32.5%, P < .001), and lower rates of cognitive impairment or dementia (0.7% vs 48.8%, P < .001), and altered mental status-related diagnosis (2.0% vs 18.8%, P < .001). Anti-agitation medication selection significantly differed based on age (P = .02). Other than lorazepam (P = .007), no significant differences were noted in the dose ordered. No significant differences were observed for safety outcomes or additional anti-agitation doses.
Conclusions: Anti-agitation prescribing practices may differ between adults aged 18 to 64 years and those aged ≥ 65 years. The findings of this study also suggest that the most common agitation etiologies may differ based on patient age. Additional higher-quality studies are needed to further explore acute agitation in older adults.
{"title":"Evaluation of Anti-Agitation Medication Prescribing Patterns by Age in the Emergency Department.","authors":"Lisa Hsi, Shannon Ruiz","doi":"10.12788/fp.0456","DOIUrl":"10.12788/fp.0456","url":null,"abstract":"<p><strong>Background: </strong>Acute agitation frequently occurs in the emergency department. Appropriate management is critical for the safety of all parties involved. Benzodiazepines and antipsychotics are commonly used for agitation, but safety concerns exist with these medications in older adults, even with acute use. The purpose of this study was to compare prescribing practices of anti-agitation medications between adults aged 18 to 64 years and those aged ≥ 65 years.</p><p><strong>Methods: </strong>This study was a retrospective chart review of patients who presented to the Veteran Affairs Southern Nevada Healthcare System emergency department and received haloperidol, droperidol, lorazepam, olanzapine, or ziprasidone from August 1, 2019, to July 31, 2022. Veterans were excluded if they had alcohol intoxication, alcohol withdrawal, benzodiazepine withdrawal, or medication administration unrelated to agitation. Safety outcomes included oxygen saturation < 95%, supplemental oxygen use, intubation, QTc prolongation, and new hypotension within 1 hour of medication administration.</p><p><strong>Results: </strong>For the 232 patients who met inclusion criteria, baseline characteristics differed significantly. When comparing patients aged 18 to 64 years and those aged ≥ 65 years, the younger cohort had higher rates of substance use disorder diagnosis (55.3% vs 27.5%, <i>P</i> < .001), positive urine drug screen (69.7% vs 22.5%, <i>P</i> < .001), and 72-hour legal hold (59.9% vs 32.5%, <i>P</i> < .001), and lower rates of cognitive impairment or dementia (0.7% vs 48.8%, <i>P</i> < .001), and altered mental status-related diagnosis (2.0% vs 18.8%, <i>P</i> < .001). Anti-agitation medication selection significantly differed based on age (<i>P</i> = .02). Other than lorazepam (<i>P</i> = .007), no significant differences were noted in the dose ordered. No significant differences were observed for safety outcomes or additional anti-agitation doses.</p><p><strong>Conclusions: </strong>Anti-agitation prescribing practices may differ between adults aged 18 to 64 years and those aged ≥ 65 years. The findings of this study also suggest that the most common agitation etiologies may differ based on patient age. Additional higher-quality studies are needed to further explore acute agitation in older adults.</p>","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":"41 Suppl 1","pages":"S16-S21"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11132097/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141177116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01Epub Date: 2024-04-15DOI: 10.12788/fp.0469
Angelica Castro, Hong-Yen Vi
Background: According to the Centers for Disease Control and Prevention, depression and schizophrenia, among other conditions, put individuals at high risk for severe COVID-19 infection. Patients at high risk often are eligible for outpatient therapies, such as antiviral and monoclonal antibody therapies, to prevent severe infection. However, depression and schizophrenia are not considered risk factors for severe COVID-19 infection at the Captain James A. Lovell Federal Health Care Center in North Chicago, Illinois, making patients with these conditions ineligible for outpatient therapy unless they have another high-risk condition.
Methods: This retrospective cohort study assessed outcomes among patients with mild-to-moderate COVID-19 to determine whether depression and/or schizophrenia impacted the risk of severe disease or negative outcomes. The primary outcome was severe COVID-19 outcomes defined as hospitalization, admission to the intensive care unit, intubation or mechanical ventilation, or death within 30 days of infection.
Results: Patients with depression or schizophrenia had more hospitalizations and deaths, but this difference was not statistically significant (P = .36). Death within 30 days of COVID-19 infection only occurred in patients with depression or schizophrenia.
Conclusions: Although there were more hospitalizations and deaths from COVID-19 within 30 days of infection among patients with depression and schizophrenia compared with individuals without these disorders, this finding was not statistically significant.
背景:根据美国疾病控制与预防中心(Centers for Disease Control and Prevention)的资料,抑郁症和精神分裂症等疾病会使患者面临严重感染 COVID-19 的高风险。高危患者通常有资格接受门诊治疗,如抗病毒和单克隆抗体治疗,以预防严重感染。然而,在伊利诺伊州北芝加哥的詹姆斯-A-洛弗尔上尉联邦医疗保健中心,抑郁症和精神分裂症并不被视为严重感染 COVID-19 的风险因素,因此患有这些疾病的患者没有资格接受门诊治疗,除非他们患有其他高风险疾病:这项回顾性队列研究评估了轻度至中度 COVID-19 患者的预后,以确定抑郁症和/或精神分裂症是否会影响重症风险或不良预后。主要结果是严重的COVID-19结果,即感染后30天内住院、入住重症监护室、插管或机械通气或死亡:结果:抑郁症或精神分裂症患者的住院和死亡人数较多,但差异无统计学意义(P = .36)。只有抑郁症或精神分裂症患者在感染 COVID-19 后 30 天内死亡:结论:尽管与无抑郁症和精神分裂症的患者相比,抑郁症和精神分裂症患者在感染 COVID-19 后 30 天内住院和死亡的人数更多,但这一结果并无统计学意义。
{"title":"Underlying Mental Illness and Risk of Severe Outcomes Associated With COVID-19.","authors":"Angelica Castro, Hong-Yen Vi","doi":"10.12788/fp.0469","DOIUrl":"10.12788/fp.0469","url":null,"abstract":"<p><strong>Background: </strong>According to the Centers for Disease Control and Prevention, depression and schizophrenia, among other conditions, put individuals at high risk for severe COVID-19 infection. Patients at high risk often are eligible for outpatient therapies, such as antiviral and monoclonal antibody therapies, to prevent severe infection. However, depression and schizophrenia are not considered risk factors for severe COVID-19 infection at the Captain James A. Lovell Federal Health Care Center in North Chicago, Illinois, making patients with these conditions ineligible for outpatient therapy unless they have another high-risk condition.</p><p><strong>Methods: </strong>This retrospective cohort study assessed outcomes among patients with mild-to-moderate COVID-19 to determine whether depression and/or schizophrenia impacted the risk of severe disease or negative outcomes. The primary outcome was severe COVID-19 outcomes defined as hospitalization, admission to the intensive care unit, intubation or mechanical ventilation, or death within 30 days of infection.</p><p><strong>Results: </strong>Patients with depression or schizophrenia had more hospitalizations and deaths, but this difference was not statistically significant (<i>P</i> = .36). Death within 30 days of COVID-19 infection only occurred in patients with depression or schizophrenia.</p><p><strong>Conclusions: </strong>Although there were more hospitalizations and deaths from COVID-19 within 30 days of infection among patients with depression and schizophrenia compared with individuals without these disorders, this finding was not statistically significant.</p>","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":"41 Suppl 1","pages":"S6-S9"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11132098/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141177118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01Epub Date: 2024-04-15DOI: 10.12788/fp.0466
Christine E Gould, Rachel L Rodriguez, Jeffrey J Gregg, Kyle Page, Luis Melendez, Joseph R Douglas, Johnny Lewis, B Josea Kramer
Background: There are significant workforce shortages for geriatric mental health care. The imbalance is particularly pronounced in the Veterans Health Administration (VHA) due to the large number of aging veterans receiving care. Workforce-based educational programs are needed to train existing clinicians to meet the mental health needs of aging veterans.
Observations: This article describes an expansion of the Geriatric Scholars Program to train VHA psychologists to care for aging veterans. The multicomponent program includes an introductory course and opportunities to apply geriatric knowledge and skills through quality improvement initiatives. The Geriatric Scholars Program-Psychology Track evolved to incorporate ongoing specialized elective learning opportunities for scholars. A webinar series extends the educational programs to reach the entire VHA workforce.
Conclusions: The Geriatric Scholars Program-Psychology Track represents a longitudinal educational approach to training VHA psychologists in clinical geropsychology. Other community-based organizations can use this model to construct and implement similar programs.
{"title":"Preparing Veterans Health Administration Psychologists to Meet the Complex Needs of Aging Veterans.","authors":"Christine E Gould, Rachel L Rodriguez, Jeffrey J Gregg, Kyle Page, Luis Melendez, Joseph R Douglas, Johnny Lewis, B Josea Kramer","doi":"10.12788/fp.0466","DOIUrl":"10.12788/fp.0466","url":null,"abstract":"<p><strong>Background: </strong>There are significant workforce shortages for geriatric mental health care. The imbalance is particularly pronounced in the Veterans Health Administration (VHA) due to the large number of aging veterans receiving care. Workforce-based educational programs are needed to train existing clinicians to meet the mental health needs of aging veterans.</p><p><strong>Observations: </strong>This article describes an expansion of the Geriatric Scholars Program to train VHA psychologists to care for aging veterans. The multicomponent program includes an introductory course and opportunities to apply geriatric knowledge and skills through quality improvement initiatives. The Geriatric Scholars Program-Psychology Track evolved to incorporate ongoing specialized elective learning opportunities for scholars. A webinar series extends the educational programs to reach the entire VHA workforce.</p><p><strong>Conclusions: </strong>The Geriatric Scholars Program-Psychology Track represents a longitudinal educational approach to training VHA psychologists in clinical geropsychology. Other community-based organizations can use this model to construct and implement similar programs.</p>","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":"41 Suppl 1","pages":"S10-S15"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11132096/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141177117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Chronicling Health Care Transformation: <i>Federal Practitioner</i> Looks Back 40 Years.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":"41 1","pages":"4-5"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11147444/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141249103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-01Epub Date: 2023-12-12DOI: 10.12788/fp.0437
Robert Dedo, Tomasz Jurga, Johnathan Barkham
Background: Heart failure (HF) is a chronic, progressive medical condition. Evidence suggests that guideline-directed medical therapy improves both morbidity and mortality in patients with HF with reduced ejection fraction when properly optimized. Unfortunately, many patients do not receive optimized therapy, highlighting the need to optimize clinicians' methods to more effectively and efficiently initiate and titrate medical therapy.
Methods: This single-center, retrospective study evaluated the rates of drug interventions prompted by the home telehealth monitoring program for veterans with HF with reduced ejection fraction. Rates of drug interventions were evaluated among those who enrolled and those who did not enroll in the program.
Results: There were 20 drug-related interventions in the home telehealth group compared with 11 interventions for the control group. One HF-related hospitalization occurred in the home telehealth program group compared with 6 in the control group.
Conclusions: This study demonstrates the potential of home telehealth to optimize veterans' medication regimens and to reduce HF-related hospitalizations. It also provides an additional catalyst to further develop home telehealth services specifically targeted at drug therapy initiation and optimization in patients with HF with reduced ejection fraction.
{"title":"VA Home Telehealth Program for Initiating and Optimizing Heart Failure Guideline-Directed Medical Therapy.","authors":"Robert Dedo, Tomasz Jurga, Johnathan Barkham","doi":"10.12788/fp.0437","DOIUrl":"10.12788/fp.0437","url":null,"abstract":"<p><strong>Background: </strong>Heart failure (HF) is a chronic, progressive medical condition. Evidence suggests that guideline-directed medical therapy improves both morbidity and mortality in patients with HF with reduced ejection fraction when properly optimized. Unfortunately, many patients do not receive optimized therapy, highlighting the need to optimize clinicians' methods to more effectively and efficiently initiate and titrate medical therapy.</p><p><strong>Methods: </strong>This single-center, retrospective study evaluated the rates of drug interventions prompted by the home telehealth monitoring program for veterans with HF with reduced ejection fraction. Rates of drug interventions were evaluated among those who enrolled and those who did not enroll in the program.</p><p><strong>Results: </strong>There were 20 drug-related interventions in the home telehealth group compared with 11 interventions for the control group. One HF-related hospitalization occurred in the home telehealth program group compared with 6 in the control group.</p><p><strong>Conclusions: </strong>This study demonstrates the potential of home telehealth to optimize veterans' medication regimens and to reduce HF-related hospitalizations. It also provides an additional catalyst to further develop home telehealth services specifically targeted at drug therapy initiation and optimization in patients with HF with reduced ejection fraction.</p>","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":"40 Suppl 6","pages":"S16-S23"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11132190/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141177130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-01Epub Date: 2023-12-13DOI: 10.12788/fp.0442
Molly E Steeves, Haley A Runeberg, Savannah R Johnson, Kevin C Kelly
Background: Long-term use of inhaled corticosteroids (ICSs) is associated with several potential adverse effects. While patients unlikely to benefit should stop ICS use, abrupt discontinuation may result in an increased risk of chronic obstructive pulmonary disease (COPD) exacerbation. Stepwise tapering may reduce this risk but data are limited, and there is no consensus on the likelihood of COPD exacerbations following ICS discontinuation. The North Texas Veterans Affairs Health Care System conducted a single center, retrospective cohort study to evaluate the rate of COPD exacerbations following the discontinuation of ICS therapy using different schedules of discontinuation.
Methods: Data were collected from the electronic health records of patients aged ≥ 40 years with a diagnosis of COPD who were on a stable dose of an ICS for ≥ 1 year that was subsequently discontinued with a last documented fill date between January 10, 2021 and September 1, 2021. Eligible patients were followed for COPD exacerbations that resulted in hospitalization until November 1, 2022. Descriptive statistics were used to evaluate characteristics of patients who experienced an exacerbation.
Results: Seventy-five patients were included: 5 (7%) experienced an exacerbation following ICS discontinuation. Age, sex, race, and ethnicity were similar for those patients who did vs did not have an exacerbation. Unexpectedly, the mean baseline eosinophil count for patients with an exacerbation was 92 cells/μL compared with 227.4 cells/μL for those without an exacerbation. Nine patients had their ICS tapered gradually, and none of them experienced an exacerbation.
Conclusions: Study findings suggest that there is a relatively low risk of COPD exacerbation following ICS discontinuation, regardless of whether a taper was performed. This result may indicate that it is reasonable to abruptly discontinue ICS in eligible patients.
{"title":"Discontinuation Schedule of Inhaled Corticosteroids in Patients With Chronic Obstructive Pulmonary Disease.","authors":"Molly E Steeves, Haley A Runeberg, Savannah R Johnson, Kevin C Kelly","doi":"10.12788/fp.0442","DOIUrl":"10.12788/fp.0442","url":null,"abstract":"<p><strong>Background: </strong>Long-term use of inhaled corticosteroids (ICSs) is associated with several potential adverse effects. While patients unlikely to benefit should stop ICS use, abrupt discontinuation may result in an increased risk of chronic obstructive pulmonary disease (COPD) exacerbation. Stepwise tapering may reduce this risk but data are limited, and there is no consensus on the likelihood of COPD exacerbations following ICS discontinuation. The North Texas Veterans Affairs Health Care System conducted a single center, retrospective cohort study to evaluate the rate of COPD exacerbations following the discontinuation of ICS therapy using different schedules of discontinuation.</p><p><strong>Methods: </strong>Data were collected from the electronic health records of patients aged ≥ 40 years with a diagnosis of COPD who were on a stable dose of an ICS for ≥ 1 year that was subsequently discontinued with a last documented fill date between January 10, 2021 and September 1, 2021. Eligible patients were followed for COPD exacerbations that resulted in hospitalization until November 1, 2022. Descriptive statistics were used to evaluate characteristics of patients who experienced an exacerbation.</p><p><strong>Results: </strong>Seventy-five patients were included: 5 (7%) experienced an exacerbation following ICS discontinuation. Age, sex, race, and ethnicity were similar for those patients who did vs did not have an exacerbation. Unexpectedly, the mean baseline eosinophil count for patients with an exacerbation was 92 cells/μL compared with 227.4 cells/μL for those without an exacerbation. Nine patients had their ICS tapered gradually, and none of them experienced an exacerbation.</p><p><strong>Conclusions: </strong>Study findings suggest that there is a relatively low risk of COPD exacerbation following ICS discontinuation, regardless of whether a taper was performed. This result may indicate that it is reasonable to abruptly discontinue ICS in eligible patients.</p>","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":"40 12","pages":"398-403"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11132102/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141177037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Semaglutide and liraglutide are glucagon-like peptide 1 receptor agonists (GLP-1 RAs) approved by the US Food and Drug Administration for patients with type II diabetes mellitus (T2DM). Patients with T2DM treated with liraglutide at the Michael E. DeBakey Veterans Affairs Medical Center (MEDVAMC) were converted to semaglutide. The primary objective was to assess changes in glycemic control and cost savings that resulted from this conversion.
Methods: We conducted a retrospective chart review of veterans without retinopathy treated at MEDVAMC between March 1, 2021, and November 30, 2021, who were converted from liraglutide 0.6 mg and 1.2 mg daily to semaglutide 0.25 mg weekly (titrated to 0.5 mg weekly after 4 weeks). We compared hemoglobin A1c (HbA1c) values at baseline and 3 to 12 months following conversion to assess glycemic control. Cost savings were evaluated using outpatient pharmacy data.
Results: During the study, 411 patients were converted from liraglutide to semaglutide; 49 additional patients met the criteria for clinician education, and 14 were converted as a result. In total, 304 patients met the criteria for inclusion. At baseline, patients' mean (SD) levels included: HbA1c, 8.1% (1.5); blood glucose, 187.4 (44.2) mg/dL; and body weight, 112.9 (23.0) kg. Three to 12 months postconversion, patients' mean (SD) HbA1c significantly decreased to 7.6% (1.4) (P < .001), blood glucose decreased to 172.6 (39.0) mg/dL (P < .001), and body weight decreased to 105.2 (32.3) kg (P < .001). Cost savings exceeding $400,000 resulted from liraglutide to semaglutide conversion.
Conclusions: Conversion of liraglutide to semaglutide led to significant HbA1c decrease and weight loss and resulted in minimal changes to patients' antihyperglycemic regimen. Common adverse effects included hypoglycemia and gastrointestinal intolerance. Due to the low conversion rate of liraglutide to semaglutide following education, a more effective method of education for clinicians to promote teleretinal imaging before conversion is warranted. Lastly, although the semaglutide cost savings initiative at MEDVAMC resulted in significant savings for the institution, a full cost-effective analysis is needed for further conclusion.
{"title":"Impact of Liraglutide to Semaglutide Conversion on Glycemic Control and Cost Savings at a Veterans Affairs Medical Center.","authors":"Maiah Hardin, Fiona Adanse, Chandler Schexnayder, Janeca Malveaux, Sylvester Agbahiwe","doi":"10.12788/fp.0413","DOIUrl":"10.12788/fp.0413","url":null,"abstract":"<p><strong>Background: </strong>Semaglutide and liraglutide are glucagon-like peptide 1 receptor agonists (GLP-1 RAs) approved by the US Food and Drug Administration for patients with type II diabetes mellitus (T2DM). Patients with T2DM treated with liraglutide at the Michael E. DeBakey Veterans Affairs Medical Center (MEDVAMC) were converted to semaglutide. The primary objective was to assess changes in glycemic control and cost savings that resulted from this conversion.</p><p><strong>Methods: </strong>We conducted a retrospective chart review of veterans without retinopathy treated at MEDVAMC between March 1, 2021, and November 30, 2021, who were converted from liraglutide 0.6 mg and 1.2 mg daily to semaglutide 0.25 mg weekly (titrated to 0.5 mg weekly after 4 weeks). We compared hemoglobin A<sub>1c</sub> (HbA<sub>1c</sub>) values at baseline and 3 to 12 months following conversion to assess glycemic control. Cost savings were evaluated using outpatient pharmacy data.</p><p><strong>Results: </strong>During the study, 411 patients were converted from liraglutide to semaglutide; 49 additional patients met the criteria for clinician education, and 14 were converted as a result. In total, 304 patients met the criteria for inclusion. At baseline, patients' mean (SD) levels included: HbA<sub>1c</sub>, 8.1% (1.5); blood glucose, 187.4 (44.2) mg/dL; and body weight, 112.9 (23.0) kg. Three to 12 months postconversion, patients' mean (SD) HbA<sub>1c</sub> significantly decreased to 7.6% (1.4) (<i>P</i> < .001), blood glucose decreased to 172.6 (39.0) mg/dL (<i>P</i> < .001), and body weight decreased to 105.2 (32.3) kg (<i>P</i> < .001). Cost savings exceeding $400,000 resulted from liraglutide to semaglutide conversion.</p><p><strong>Conclusions: </strong>Conversion of liraglutide to semaglutide led to significant HbA<sub>1c</sub> decrease and weight loss and resulted in minimal changes to patients' antihyperglycemic regimen. Common adverse effects included hypoglycemia and gastrointestinal intolerance. Due to the low conversion rate of liraglutide to semaglutide following education, a more effective method of education for clinicians to promote teleretinal imaging before conversion is warranted. Lastly, although the semaglutide cost savings initiative at MEDVAMC resulted in significant savings for the institution, a full cost-effective analysis is needed for further conclusion.</p>","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":"40 Suppl 6","pages":"S24-S30"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11132191/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141177049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}